Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

NCT06532591 | Recruiting Phase 2

• 1 other identifier: EK2024001
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to observe and evaluate the efficacy and safety of cadonilimab combined with chemotherapy in patients with resectable IB (≥ 4cm) - IIIB (N2) stage PD-L1 negative non-small cell lung cancer

Conditions

NSCLC

Outcome Measures

Primary Outcomes (1)

• Major pathological response (MPR)

  MPR is defined as the percentage of residual viable tumour cells (%RVT) in the tumour bed of no more than 10%.

  At time of surgery

Secondary Outcomes (4)

• Pathologic complete response (pCR)

  At time of surgery

• Objective response rate (ORR)

  Up to 1 year

• Event free survival at 24 months (EFS24)

  Up to 2 year

• Treatment-Emergent Adverse Event (TEAE)

  Up to 2 year

Study Arms (1)

Experimental: Cadonilimab +Paclitaxel/ Albumin-bound paclitaxel +Carboplatin

EXPERIMENTAL

Drug:Cadonilimab +Paclitaxel/ Albumin-bound paclitaxel+Carboplatin neoadjuvant chemotherapy\[Cadonilimab, 10mg/kg ,d1,q3w; Paclitaxel 175mg/m2 ivgtt d1/Albumin-bound paclitaxel 260mg/m2,ivgtt(\>30min) ,d1,q3w; carboplatin AUC 5 ivgtt d1, q3w\] for 3 cycles.The patient was evaluated after 3 cycles of neoadjuvant chemotherapy. The surgery was performed 3-6 weeks after the completion of neoadjuvant chemotherapy. After surgery patients could receive up to 12 months of adjuvant chemotherapy.

Drug: cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin

Interventions

cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin DRUG

PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w

Experimental: Cadonilimab +Paclitaxel/ Albumin-bound paclitaxel +Carboplatin

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years and ≤ 70 years
• Patients with non-small cell lung cancer diagnosed by pathologic histology or cytology, and the primary focus or lymph node metastasis test is clearly negative for EGFR/ALK/ROS1;
• Tumor tissue PD-L1 expression TPS \<1%
• Patients with resectable stage IB (≥4 cm) to IIIB (N2) NSCLC (according to the staging criteria of the American Joint Committee on Cancer, 7th edition)
• Eastern Cooperative Oncology Group performance-status score of 0 or 1
• No previous anticancer therapy
• Patients had to have measurable disease according to the Response Evaluation Criteria in Solid Tumors, version 1.1, and pretreatment tumor tissue available to assess the expression of programmed death ligand 1 (PD-L1)
• Normal function of major organs

You may not qualify if:

• Patients with large cell carcinoma and mixed cell lung cancer, mixed with small cell lung cancer components;
• Presence of locally advanced unresectable or metastatic disease;
• Patients in whom imaging shows that the tumor has invaded a vital vascular perimeter or in whom, in the judgment of the investigator, there is a high likelihood that the tumor will invade a vital vessel and cause a fatal hemorrhage during the follow-up study; or patients in whom there is a significant cavitating or necrotic tumor in the lung;
• Has undergone any systemic anticancer therapy for NSCLC, including cytotoxic drug therapy, immunologic drug therapy, experimental therapy;
• Has undergone localized radiotherapy for NSCLC;
• Patients who have had a cancer other than NSCLC in the five years prior to the start of treatment in this study. Patients with cancers other than NSCLC within five years prior to the start of treatment in this study. Excluding cervical carcinoma in situ, cured basal cell carcinoma, and epithelial tumors of the bladder \[including Ta and Tis\];
• Allergy to cardunculizumab or any component of the chemotherapeutic agent;
• Patients with the presence of any severe and/or uncontrolled disease
• Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy, or any active interstitial lung disease with clinical evidence;
• Patients who have had a cerebrovascular accident (including temporary ischemic attack) and pulmonary embolism within 6 months;
• Current peripheral neuropathy of ≥ CTCAE grade 2, except as a result of trauma; patients requiring total right lung resection; subjects who have had major surgery or severe trauma and whose effects of surgery or trauma have resolved less than 14 days prior to enrollment
• Patients who are participating in another clinical study or who are less than 4 weeks from the end of treatment in the previous clinical study;
• History of known severe hypersensitivity reactions to other monoclonal antibodies;
• Pregnant or lactating women;
• Previous history of definite neurologic or psychiatric disorders, including epilepsy or dementia;

Sponsors & Collaborators

• Sichuan Cancer Hospital and Research Institute: lead

Study Sites (1)

Sichuan Provincial Tumor Hospital

Chengdu, Sichuan, 610000, China

RECRUITING

Central Study Contacts

Li Juan, Ph.D

CONTACT

138 8027 6636; dr.lijuan@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor of Oncology

Study Record Dates

• First Submitted: April 10, 2024
• First Posted: August 1, 2024
• Study Start: August 1, 2024
• Primary Completion: April 30, 2025
• Study Completion: October 1, 2025
• Last Updated: December 20, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)